Sununary The expression of mdrl gene product P-glycoprotein (P-gp) was investigated in 53 normal and reactive bone marrows by means of immunocytochemistry, using the monoclonal antibody (mAb) C219 and the alkaline phosphatase anti-alkaline phosphatase method. In a limited number of patients, data were confirmed by using the mAb MRK16 or a polymerase chain reaction assay for mdrl gene expression. There was no history of prior chemotherapy or any malignancy in this group. Bone marrow aspirates were obtained as part of a routine diagnostic programme in bone marrow donors or in patients presenting with a variety of diagnoses such as unexplained gammopathy, fever, anaemia, other changes in peripheral blood smear, rheumatoid arthritis, vasculitis, or urticaria pigmentosa. Morphologically the bone marrow was normal in 23 patients, a megaloblastic erythropoiesis was seen in two patients and unspecific changes were seen in 28 patients. Twenty-seven of 53 samples were found to be positive for P-gp expression with the percentage of positive cells ranging from 2%-80% (mean = 24%). With a cutoff point of 10%, five of 23 normal (22%) and 13 of 28 reactive bone marrows (46%) were considered positive for P-gp expression. There was no obvious correlation between diagnosis or age and P-gp expression. Additional staining for the early surface marker CD-34 was performed in 12 samples, with none of them revealing more than 1% positivity. Since P-gp expression has so far been described only in CD-34 positive bone marrow cells, data suggest that P-gp expression may be reinduced in CD-34 negative cells under conditions which remain to be determined.
The phenomenon of multidrug resistance (mdr) is manifested by cross resistance to a number of structurally and functionally unrelated lipophilic drugs and has been functionally associated with the expression of a plasma membrane energy dependent efflux pump with broad substrate specificity, termed P-glycoprotein (P-gp), which is the product of the mdrl gene. Overexpression of the mdrl gene is associated with decreased sensitivity of tumour cells to natural product drugs such as anthracyclines, Vinca alkaloids and epipodophyllotoxins, due to increased energy-dependent drug efflux. The mdr-phenotype has been frequently observed in a number of human tumours (Noonan et al., 1990; Schneider et al., 1989; Chan et al., 1990; Bak et al., 1990 ) and haematologic malignancies (Dalton et al., 1989; Pirker et al., 1989; Holmes et al., 1989; Holmes et al., 1990) , both untreated and treated with chemotherapeutic drugs and may be a major reason for the failure of cancer chemotherapy. On the other hand overexpression of the P-gp has been found in a variety of normal human tissues, including the liver, jejunum, colon, kidney, the adrenal cortex, the secretory epithelium of the uterus and endothelial cells in the brain (Thiebaut et al., 1987; Arceci et al., 1990; Sugawara et al., 1988; Cordon-Cardo et al., 1989) . The function and regulation of the P-gp in these organs is not yet fully understood but it may include excretion of toxic substances as well as other normal metabolites thus serving the body as a major and general route of detoxification. Although mdrl gene expression in normal bone marrow cells has been described to be low or negative (Dalton et al., 1989; Noonan et al., 1990; Fojo et al., 1987) , the mdrl gene expression in de novo nonlymphoblastic acute leukaemia at diagnosis seems to be a frequent event. Depending on the method of detection, 46% to 71% of leukaemia samples are found to be positive for mdrl expression (Kuwazuru et al., 1990; Pirker et al., 1991; Campos et al., 1992) . Furthermore, there seemed to be a good correlation between the detection of the mdr-phenotype and clinical outcome. To deepen the knowledge of the exact nature of the high incidence of the mdr-phenotype in de novo acute leukaemia, it therefore seemed interesting to check for mdrl gene expression in other than leukaemic bone marrows.
Since CD-34 antigen positive hematopoetic stem cells (Chaudhary & Roninson, 1991) as well as total nucleated peripheral blood cells and peripheral blood lymphocytes (Holmes et al., 1990; Neyfakh et al., 1989) were recently reported to express the mdrl gene it seemed likely to find the mdr-phenotype not only in haematologic malignancies but also in bone marrows without malignant infiltrative disorders. To prove this hypothesis we looked for P-gp expression in normal bone marrows as well as in reactive marrows with unspecific changes using the monoclonal antibodies C219 and MRK16 and immunocytochemistry. To confirm the results, we have analysed mdrl mRNA expression by polymerase chain reaction (PCR) amplification in a limited number of patients. A selected number of patients was also tested for CD-34 antigen expression using the monoclonal antibody 8G12. There was no history of prior chemotherapy or any malignancy in the group of 53 patients tested.
Material and methods

Patients
Bone marrow aspirates were performed after informed consent as part of a routine diagnostic programme in 53 patients who came to our outpatient department for various reasons (see Table I for details) such as planned bone marrow donation (9), gammopathy of undetermined origin (8), fever (2) or anaemia (6), leukopenia (2) or leukocytosis (1), thrombocytopenia (3) or thrombocytosis (1), polycythemia (2), recurrent viral infections (1), vasculitis (4) or suspected vasculitis (3), suspected haemoblastosis (1), suspected mycosis fungoides (2), osteolytic lesions of undetermined origin (1), rheumatoid arthritis (2), acne conglobata (1), suspected Paget's disease (1) or urticaria pigmentosa (3).
The group consisted of 26 men and 27 women. The ages ranged from 15 to 87 with a mean age of 48 years.
Patient cells Bone marrow smears were prepared from each patient. After being air dried they were stained with May-GrunwaldGiemsa. For immunocytochemical staining cell suspensions of bone marrow cells enriched by Ficoll-Hypaque density gradient centrifugation were either used right away or were cryopreserved in liquid nitrogen until studied. (Kartner et al., 1983 ), served as negative or positive control for antibody staining. Cells were maintained at a density of 2-5 x 105 cells ml-' in RPMI-1640 media, supplemented with 5% penicillin-streptomycin, 5% of 200 mM L-glutamine, 10% foetal calf serum and, for CEM/ VBL100, with 100 ng ml-' vinblastine.
Monoclonal antibodies to P-glycoprotein 170 Two monoclonal antibodies known to recognise P-gp were used. C219 (Centocor, Malvern, Pennsylvania) identifies a cytoplasmic component of the P-gp (Kartner et al., 1985) , whereas MRK16 (kindly provided by T. Tsuruo) is directed at an external cellular P-gp 170 epitope (Hamada & Tsuruo, 1986 (Thiebaut et al., 1989) or contamination of at least some lots of purified C219 with an anti-A-blood group antibody (Finstad et al., 1991) , results were crosschecked in 24 patients by staining with MRK16 (Table I ). An example of immunostaining is given in Figure  1 . As reported before (Wishart et al., 1990) , staining with C219 was more intense than with MRK16. The staining intensity could be increased by repeating two steps of the APAAP-method for those slides having been incubated with MRK16. Nevertheless the pattern of expression did not differ significantly and cells stained clearly positive or negative regardless of the antibody used. Furthermore, a PCR assay for mdrl gene expression was performed in three C219 negative (patient 18,38,45) and five C219 positive (patient 31, 43, 44, 46, 48) samples to confirm results on the mRNAlevel (Figure 2) . In seven of these samples the degree of P-gp expression had also been confirmed by staining with MRK16. Results for immunocytochemistry and PCR were in complete concordance for all samples except 18, the latter having 2% staining positivity for MRK16, which, in view of the negative results for C219 and PCR was probably due to unspecific binding. To examine a possible relationship between P-gp expression and positivity for the early marker CD-34, twelve samples were additionally stained with the monoclonal antibody 8G12 of which seven (patient 1, 8, 16, 18, 19, 20, 30) (Pirker et al., 1989; Noonan et al., 1990; Fojo et al., 1987) . This discrepancy might be due to different methods of detection. Certain molecular techniques are probably not sensitive enough to detect mdrl gene expression in a small population of mdrl positive cells. In contrast, immunocytochemistry allows detection in single or small numbers of cells. Furthermore, in those studies mentioned above, only a small number of bone marrow samples of healthy volunteers was the subject of investigation whereas in our study a substantial number of samples was taken from patients presenting with some history of preceding disease. In this context it also seems of interest that with a cutoff point of 10%, P-gp expression was detected in nearly half of the samples demonstrating reactive changes whereas this was the case in only 22% of the normal marrows.
In their recently published paper Chaudhary and Roninson (1991) found P-gp expressed in practically all haematopoetic progenitor cells of the bone marrow with the highest level of Table I . The reaction products were analysed by 2% agarose gel electrophoresis and ethidium bromide staining. DNA fragments generated from single-stranded cDNA sythesised from RNA by reverse transcriptase, were amplified by 30 to 32 cycles of PCR. Fragments of 167 bp were generated from cDNA of the multidrug-resistant cell line CEM/VBL 100 and five patients by using the mdrl specific primer set. Fragments of 120 bp were generated in all samples by using the beta2-microglobulin (2 m) specific primer set.
P-gp in those cells displaying characteristics of pluripotent stem cells, as defined by CD-34 antigen expression (Civin et al., 1984) . There was a positive correlation between the level of CD-34 expression on the one hand and P-gp expression on the other hand whereas those cells which became CD-34 negative lost P-gp expression. Chaudhary and Roninson (1991) for CD-34 positive cells.
Since we found P-gp expression more often in those bone marrow samples which showed reactive changes one could also hypothesise on a specific function of the efflux pump regarding substances that might contribute to these changes. This seems even more likely since the mdrl gene is expressed in several normal tissues associated with secretory or barrier functions and could thus play a significant role in these processes.
The presence of P-gp in a broad variety of normal tissues and its possible function as a general detoxification system of the body makes it even more feasible that cells of the human bone marrow should use a similar mechanism for detoxification. To further investigate the role of P-gp and the mechanism(s) of reinduction in CD-34 antigen negative cells it would be of interest to determine whether P-gp expression is lineage specific and whether the pattern of expression in reactive bone marrows differs from what can be seen in normal bone marrows. This work was supported by a grant from the German Research Council (DFG He 1525/2-1).
